ClinicalTrials.gg
CompletedNCT00016198Updated Jun 26, 2013

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

A Phase 2 interventional study of FOLFOX regimen and fluorouracil in Colorectal Cancer, sponsored by Prologue Research International. Completed at 74 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-26.

Sponsored by Prologue Research International · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Started
2001
with 12 others
Phase 2
79 of 159
6 open now
Registered
32nd of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is one of 13 that started in 2001, is one of 79 in phase 2, and was the 32nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of combining fluorouracil and leucovorin with or without oxaliplatin in treating patients who have recurrent metastatic colorectal cancer.

Read the detailed description

OBJECTIVES: I. Compare the overall response rate and overall survival of patients with recurrent metastatic colorectal adenocarcinoma treated with third-line therapy comprising fluorouracil and leucovorin calcium with or without oxaliplatin. II. Compare the onset and duration of complete and partial responses and duration of disease stabilization in patients treated with these regimens. III. Compare the proportion of patients with stable disease and proportion of patients with tumor-related symptomatic improvement treated with these regimens. IV. Compare the time to disease progression and time to tumor-related symptomatic worsening in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 2-4 minutes followed by fluorouracil IV continuously over 22 hours on days 1 and 2. Arm II: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 2-4 minutes followed by fluorouracil IV continuously over 22 hours on day 1. On day 2, patients receive leucovorin calcium and fluorouracil as in arm I. Treatment in both arms repeats every 2 weeks for at least 1 year in the absence of disease progression. Patients are followed at day 30 and then for approximately 6 months.

PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this study.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • stage IV colon cancer
  • stage IV rectal cancer
  • recurrent colon cancer
  • recurrent rectal cancer
  • adenocarcinoma of the colon
  • adenocarcinoma of the rectum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS: or cytologically confirmed adenocarcinoma of the colon or rectum /recurrent disease not amenable to potentially curative therapy (e.g., inoperable metastatic disease) Documented sequential disease progression (by CT scan or MRI) after 2 prior chemotherapy regimens for metastatic/recurrent disease At least 1 unidimensionally At least 20 mm by conventional CT scan or MRI OR At least 10 mm by spiral CT scan Must have received prior fluorouracil (or capecitabine) and leucovorin calcium with or without irinotecan as therapy and irinotecan with or without fluorouracil (or capecitabine) and leucovorin calcium as second-line therapy for metastatic disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 50-100% : Not specified Hematopoietic: at least 1,500/mm3 count at least 100,000/mm3 Hepatic: no greater than 1.5 times (ULN) and SGPT no greater than 2 times ULN (6 times ULN if documented liver metastases present) Alkaline phosphatase no greater than 2 times ULN (6 times ULN if documented liver metastases present) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No class III or IV symptomatic congestive heart failure No serious cardiac arrhythmia No unstable angina No myocardial infarction within the past 6 months Pulmonary: No interstitial pneumonia No extensive and symptomatic fibrosis of the lung Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective during and for 6 months after study No known peripheral neuropathy (absence of deep tendon reflexes as the sole neurologic abnormality allowed) No diabetes or active infection No known dihydropyrimidine dehydrogenase deficiency

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior anticancer biologic therapy Chemotherapy: See Disease Characteristics No prior oxaliplatin No prior adjuvant irinotecan Prior adjuvant fluorouracil and leucovorin calcium allowed At least 3 weeks since prior chemotherapy (e.g., second-line irinotecan with or without fluorouracil (or capecitabine) and leucovorin calcium) for metastatic disease and recovered Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy No prior radiotherapy to target lesion unless documented progression within the radiation portal Surgery: See Disease Characteristics At least 4 weeks since prior surgery for primary tumor or metastases and recovered Other: No prior anticancer drug No other concurrent investigational agents

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
06

Study locations

74 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Arkansas Cancer Clinic, P.A.
    Pine Bluff, Arkansas 71603, United States
  • Citrus Valley Medical Center
    Covina, California 92807, United States
  • Cancer Center and Beckman Research Institute, City of Hope
    Duarte, California 91010-3000, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Comprehensive Cancer Centers of the Desert
    Palm Springs, California 92262, United States
  • Kaiser Permanente-Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • Kaiser Permanente Medical Center - Vallejo
    Vallejo, California 94589, United States
  • John Muir Medical Center
    Walnut Creek, California 94598, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Northwestern Connecticut Oncology-Hematology Associates
    Torrington, Connecticut 06790, United States
  • Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Center for Hematology-Oncology
    Boca Raton, Florida 33486, United States
  • Halifax Medical Center
    Daytona Beach, Florida 32114, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Hematology/Oncology Associates
    Jacksonville, Florida 32216, United States
  • Lake Heart and Cancer Medical Center
    Leesburg, Florida 34748, United States
  • Oncology-Hematology Group of South Florida
    Miami, Florida 33176, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Hematology/Oncology Associates
    Port Saint Lucie, Florida 34952, United States
  • Northwest Medical Specialists, P.C.
    Arlington Heights, Illinois 60004, United States
  • Dreyer Medical Clinic
    Aurora, Illinois 60506, United States
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University
    Chicago, Illinois 60611-3013, United States
  • Cancer Care Specialists of Central Illinois, S.C.
    Decatur, Illinois 62526, United States
  • Hope Center
    Terre Haute, Indiana 47809, United States
  • Medical Oncology and Hematology Associates
    Des Moines, Iowa 50309, United States
  • Mercy Cancer Center
    Mason City, Iowa 50401, United States
  • Lucille Parker Markey Cancer Center, University of Kentucky
    Lexington, Kentucky 40536-0093, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Baton Rouge General Medical Center
    Baton Rouge, Louisiana 70821-2511, United States
  • Cancer and Blood Institute
    Metairie, Louisiana 70006, United States
  • Saints Memorial Medical Center
    Lowell, Massachusetts 01852, United States
  • Saint Joseph Mercy Hospital
    Ann Arbor, Michigan 48106, United States
  • Medical Oncology Group
    Gulfport, Mississippi 39501, United States
  • Jackson Oncology Associates, PLLC
    Jackson, Mississippi 39202, United States
  • St. Joseph Oncology, Inc.
    Saint Joseph, Missouri 64506, United States
  • Deaconess Billings Clinic
    Billings, Montana 59107-5100, United States
  • Monmouth Medical Center
    Long Branch, New Jersey 07740-6395, United States
  • Jersey Shore Cancer Center
    Neptune, New Jersey 07753, United States
  • Central Jersey Oncology Center
    New Brunswick, New Jersey 08901, United States
  • Hematology Associates of New Jersey, P.A.
    Ridgewood, New Jersey 07450, United States
  • Monmouth Hematology-Oncology Associates, P.A.
    West Long Branch, New Jersey 07764, United States
  • University of New Mexico Cancer Research & Treatment Center
    Albuquerque, New Mexico 87131, United States
  • Albert Einstein Comprehensive Cancer Center
    Bronx, New York 10461, United States
  • HemOnCare, P.C.
    Brooklyn, New York 11235, United States
  • North Shore Hematology/Oncology Associates, P.C.
    East Setauket, New York 11733, United States
  • Reddy Cancer Treatment Center
    Malone, New York 12953, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Interlakes Oncology/Hematology PC
    Rochester, New York 14623, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • South Shore Hematology Oncology Associates, P.C.
    Rockville Centre, New York 11570, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Mid-Ohio Oncology/Hematology, Inc.
    Columbus, Ohio 43213, United States
  • Hematology Oncology Consultants Inc
    Columbus, Ohio 43235, United States
  • Lawrence M. Stallings Medical Practice
    Wooster, Ohio 44691, United States
  • Oklahoma Oncology Inc.
    Tulsa, Oklahoma 74104, United States
  • Bend Memorial Clinic
    Bend, Oregon 97701, United States
  • Salem Hospital Regional Cancer Center
    Salem, Oregon 97309-5014, United States
  • Oncology Hematology of Lehigh Valley, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Pennsylvania Oncology Hematology Associates
    Philadelphia, Pennsylvania 19107, United States
  • Lifespan: The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Memorial Hospital Cancer Center - Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Family Cancer Center
    Collierville, Tennessee 38017, United States
  • Baptist Regional Cancer Center
    Knoxville, Tennessee 37920, United States
  • West Cancer Clinic
    Memphis, Tennessee 38120, United States
  • Center for Oncology Research and Treatment, Medical City Hospital
    Dallas, Texas 75230, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 78229, United States
  • Scott and White Memorial Hospital
    Temple, Texas 76508, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Intermountain Hematology/Oncology Associates, Inc.
    Salt Lake City, Utah 84124, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2001, a primary completion of Apr 2003 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2001
First posted
Jan 7, 2004
Start
May 2001
Primary completionActual
Apr 2003
CompletionActual
Dec 2010
Last update
Jun 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00016198
Lead sponsor
Prologue Research International
First posted
Jan 7, 2004
Start date
May 2001
Primary completion
Apr 2003
Completion
Dec 2010
Last update
Jun 26, 2013

Study contacts

Richard A. Gams, MD
study chair · Prologue Research International
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Oxaliplatin

Start the discussion